Terms: = Lymphoma AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Prognosis
10 results:
1. Single-cell profiling of T cells uncovers a tissue-resident memory-like T-cell subset associated with bidirectional prognosis for B-cell acute lymphoblastic leukemia.
Lai W; Wang X; Liu L; Xu L; Mao L; Tan J; Zha X; Zhan H; Lei W; Lan Y; Chen G; Li Y; Luo OJ
Front Immunol; 2022; 13():957436. PubMed ID: 36532049
[TBL] [Abstract] [Full Text] [Related]
2. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
[TBL] [Abstract] [Full Text] [Related]
3. 25-Hydroxy vitamin D deficiency predicts inferior prognosis in Hodgkin lymphoma.
Qin JQ; Yin H; Wu JZ; Chen RZ; Xia Y; Wang L; Zhu HY; Fan L; Li JY; Liang JH; Xu W
Leuk Res; 2021 Jun; 105():106580. PubMed ID: 33836479
[TBL] [Abstract] [Full Text] [Related]
4. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract] [Full Text] [Related]
5. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical outcomes of peripheral blood stem cell transplantation for aggressive peripheral T-cell lymphoma].
Huang WR; Gu ZY; Li HH; Bo J; Wang SH; Li F; Gao XN; Dou LP; Zhao Y; Jing Y; Zhu HY; Wang QS; Yu L; Gao CJ; Liu DH
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):729-733. PubMed ID: 30369182
[No Abstract] [Full Text] [Related]
7. Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma.
Thompson CA; Yost KJ; Maurer MJ; Allmer C; Farooq U; Habermann TM; Inwards DJ; Macon WR; Link BK; Rosenthal AC; Cerhan JR
Hematol Oncol; 2018 Dec; 36(5):749-756. PubMed ID: 29862550
[TBL] [Abstract] [Full Text] [Related]
8. [Characteristics and Prognostic Significance of Cytogenetic Abnormalities in Diffuse Large B-Cell lymphoma Patients with Bone Marrow Involvement].
Liu W; Lyu R; Huang WY; Li CW; Liu H; Li J; Zou DH; Qiu LG; Yi SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):761-765. PubMed ID: 28641631
[TBL] [Abstract] [Full Text] [Related]
9. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract] [Full Text] [Related]
10. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract] [Full Text] [Related]
